On February 1, 2013, Hyperion Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved Ravicti™ (glycerol phenylbutyrate) for the treatment of Urea Cycle Disorders in adult and pediatric patients two years of age and older. The drug is expected to be commercially available to physicians and patients by the end of April 2013. A copy of the press release is filed as Exhibit 99.2 to this Current Report and is incorporated herein by reference.

The Company is filing the risk factors for the purpose of updating and superseding the risk factor disclosure contained in its prior public filings, including those discussed under the caption "Risk Factors" in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012, which was filed with the SEC on November 7, 2012. The updated risk factors are filed as Exhibit 99.2 to this Current Report and are incorporated herein by reference.

(d) Exhibits.

                 Exhibit
                 Number    Description

                 99.1      Press Release, dated February 1, 2013

                 99.2      Risk Factors